TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two...

Related Keywords

Australia ,United States ,Sydney ,New South Wales ,France ,American ,Michael Esquerre ,Joel Tuyaret ,Michael Fitzgerald ,Marie Mandron Evotec ,Philippe Cassier ,Maha Ayyoub ,Philippe Rochaix ,Lise Davenne ,Pierre Benoit Ancey ,Clara Maria Scarlata ,Nathalie Delesque Touchard ,Marie Mandron ,Carlos Gomez Roca ,Christophe Caux ,Pierre Fons ,Jean Pierre Delord ,Gaelle Badet ,Pierre Fons Evotec ,Myriam Estrabaut ,James Garner ,Adamc Smith ,Celine Poussereau Pomie ,Amy Klawitter ,Kazia Therapeutics Limited ,Prnewswire Kazia Therapeutics Limited ,Genentech ,Kazia Therapeutics ,Therapeutics Limited ,Annual Meeting ,American Association ,Cancer Research ,New Orleans ,Gomez Roca ,Leesa Gentry ,Orphan Drug Designation ,Fast Track Designation ,Rare Pediatric Disease Designation ,Orphan Designation ,Chief Executive Officer ,